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Abstract
Purpose FDG PET/CT is an excellent tool to detect melanoma
metastases and also allows quantification of FDG uptake using
standardized uptake value (SUV). The aim of this study was to
prospectively investigate the potential prognostic value of SUV
for disease-free survival (DFS) and disease-specific survival
(DSS) for patients with stage IIIB melanoma.
Methods From November 2003 to March 2008, all consec-
utive patients were included in the present study. Inclusion
criteria were: palpable, histology- or cytology-proven lymph
node metastases of melanoma, and referred to the University
Medical Centre Groningen for FDG PET and CT examina-
tion. Patients without distant metastases were evaluated.
Multivariable survival analysis was performed to determine
whether SUV was associated with DFS and DSS (Cox
proportional hazard analysis).
Results In 80 patients (without distant metastases, 65 %)
SUV could be measured. Overall 5-year DFS was 41 %
(95% CI 26–56 %) and 24 % (95% CI 12–38 %) in patients
with a low and high SUVmean (p00.02), respectively.
Overall 5-year DSS was 48 % (95% CI 31–62 %) and
30 % (95% CI 17–45 %) in patients with a low and high
SUVmean (p00.04), respectively. In the multivariable anal-
ysis, SUVmean was associated with DFS (hazard ratio 1.7;
p00.048), but was not associated with DSS (hazard ratio
1.6; p00.1). The number of positive nodes, extranodal
growth and gender were also associated with survival.
Conclusion FDG uptake in clinically overt nodal melanoma
metastases is inversely associated with DFS. Univariate
analysis showed an association with DSS. However, after
adjustment for potential confounders this association was no
longer significant. If these findings are confirmed in larger
studies, SUVmean could potentially be used (in addition to the
number of positive nodes, tumour size and extranodal growth)
as a factor in deciding on adjuvant systemic treatment.
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Introduction
Melanoma is a tumour with one of the most rapidly increas-
ing incidence rates, especially in Caucasian populations. In
a decade, its incidence in the Netherlands has risen by 63 %
to 21.7/100,000 (European standardized rate) from 13.3/
100,000 in 1998 [1]. Standard treatment for patients with
palpable lymph node metastases (AJCC stage IIIB) is ther-
apeutic lymph node dissection (TLND). However, these
patients are at high risk of developing distant metastases.
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Established prognostic factors in patients with stage IIIB
melanoma are the number and size of metastatic nodes,
and the presence of extranodal growth [2, 3]. Identification
of additional prognostic factors could lead to more individ-
ualized treatment and follow-up schemes.
Whole-body 18F-FDG PET is a sensitive screening tool
in patients with high-risk melanoma, since melanomas are
typically FDG-avid [4]. The added value of FDG PET over
CT with respect to diagnostic accuracy and impact on man-
agement has been established in several studies [4–10].
Besides improved detection of metastases, a standard clinical
PET/CT scan offers the opportunity to quantify the level of
glucose metabolism in tumours. Glucose metabolism, as
assessed with FDG, is an epiphenomenon of cancer and seems
to have prognostic value [11–17]. However, the value of FDG
as a prognostic biomarker is not undisputed [18], probably as
a consequence of confounding and heterogeneity in both the
clinical spectrum and PET technology. We have reported
some preliminary data acquired in a retrospective setting
suggesting an inverse relationship between tumour FDG up-
take in patients with stage III melanoma who receive surgery
with curative intent [13]. The present study aimed to prospec-




From November 2003 until March 2008, all patients with
palpable, histology- or cytology-proven lymph node metas-
tases of melanoma referred to the University Medical Centre
Groningen (UMCG) for FDG PET and CT examination
were prospectively included in this study. Prior to study
entry, all patients were considered candidates for TLND,
and they took part in a large prospective multicentre study
to assess the diagnostic performance of FDG PET and multi-
slice CT [4]. Inclusion criteria for the present study were: stage
III after FDG PET and abdominal/thoracic CT, candidate for
TLNDwith curative intent, and scanned on the same FDG PET
scanner with identical patient preparation, acquisition
and reconstruction protocols. Patients with diabetes were
not included. The study was approved by the UMCG
Medical Ethics Committee. Patients were actively followed up
until January 2012. Follow-up was uniform in all patients and
consisted of clinical evaluation of physical signs and symp-
toms at standard follow-up visits (every 3 months in the first
year, every 4 months in the second year, twice a year in the
third to fifth years, and every year in the sixth to tenth years);
diagnostic tests (chest radiography, CT or FDG PET) were
only indicated if distant metastases were suspected.
FDG PET and SUV
FDG was synthesized on-site according to the method de-
scribed by Hamacher et al. using an automated synthesis
module [19]. Prior to FDG PET imaging, patients were
instructed to fast for at least 6 h and to drink 1 l of water.
After intravenous injection of FDG, whole-body imaging
was performed in the two-dimensional mode using a
Siemens ECAT EXACT HR+ scanner (Siemens/CTI,
Knoxville, TN), applying emission scans of 5 min per
bed position, starting 90 min after the injection of FDG.
Image reconstructions were iterative (ordered subset expecta-
tion maximization ) with eight subsets and two iterations. The
image matrix size was 128 and the voxel size was 5.0. All
scans were corrected for decay, scatter, randoms and attenua-
tion, and normalized. The postreconstruction filter (gaussian
postprocessing filter) was 5 mm, yielding an estimated spatial
resolution (full-width at half-maximum) of 7 mm.
FDG uptake was calculated as SUV (radioactivity concen-
tration in tissue in becquerels per cubic centimetre/injected
dose in becquerels/patient body weight in grams). Three-
dimensional volumes of interest were placed semiautomati-
cally around the lymph node metastasis with the highest FDG
uptake (visual assessment) using dedicated software (IDL-
Viewer, Leuven). The numerator of the SUV was chosen to
measure either the mean counts within an isocontour to 70 %
of the voxels with the highest counts, or the maximum itself,
yielding SUVmean or SUVmax, respectively.
Data analysis
To explore the distribution of SUVmean and SUVmax a
kernel density plot was used, which approximates the prob-
ability density of the variable; Kernel density plots have the
advantage of being independent of the choice of origin,
unlike histograms. The associations between SUVmean/
SUVmax or the log-transformation (which gave the best
fit) and patient characteristics were assessed using Student’s
t-test or analysis of variance. Patients were divided into two
groups (high and low SUV) based on the median value of
the log(SUVmean) and log(SUVmax) for the survival analysis.
This dichotomization led to the same patient categorization for
SUVmax and SUVmean in 95 % of the patients. Since repeat-
ability of SUVmean is superior to that of SUVmax [20, 21], we
show the SUVmean results in the analyses.
Survival was analysed in terms of disease-free survival
(DFS) and disease-specific survival (DSS). Differences in
survival were assessed using the log-rank test. For DFS an
event was recorded for any recurrence; for DSS an event
was recorded if the patient died due to melanoma metastases.
Multivariable Cox proportional hazard analysis was per-
formed to determine independent prognostic factors. Multi-
variable models were created with age, gender, location of the
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lymph nodes defined as cervical region, axilla or groin, num-
ber of nodes removed during TLND, number of lymph nodes
positive on histopathology after TLND, tumour size in the
largest lymph node metastasis determined after TLND by
histopathology, extranodal growth defined as metastatic
tumour which clearly extended (histologically) through the
nodal capsule into the perinodal fatty tissue or tumour involve-
ment in the hilar region with interruption of the smooth outline
of the (presumed) capsule, Breslow thickness and ulceration of
the primary melanoma, and high or low SUVmean. The pro-
portional hazard assumption was tested for the multivariable
models. All p-values were considered significant if p<0.05.
Results
A total of 80 patients were included in the present study.
There were no patients lost to follow-up. Table 1 shows the
characteristics of this cohort. There were slightly more
women: 41 women (51.2 %), 39 men (48.8 %). Their
median age was 57.0 years (range 24.7–93.2 years). Lymph
node metastases were located in the groin (55.0 %), axilla
(32.5 %) or cervical region (12.5 %). The median number of
removed nodes was 16 (range 7–48) and the median number
of positive nodes was 2 (range 1–19). The tumour size in the
lymph node ranged from 0.5 to 7.0 cm with a median of
3.1 cm. In 25 patients (31.2 %) extranodal growth was
recorded.
As shown in Fig. 1, the SUV values were not normally
distributed (no gaussian distribution). A log-transformation
of the SUVmean and SUVmax values provided the best fit
to a Gaussian distribution. The log-transformed SUV-
mean and SUVmax values were not associated with
gender (p00.3 and p00.4), age (p00.2 and p00.1),
location of the lymph nodes (p00.2 for both), number
of removed nodes (p00.4 for both), number of positive
nodes (p00.1 for both) or extranodal growth (p00.6 for
both), respectively. SUV was, however, associated with size
of the melanoma metastasis in the lymph node (p<0.001).
Survival
During the follow-up (median 3.0 years, range: 0.3–
8.2 years, in all patients; 5.5 years, 3.1–8.2 years, in patients
without an event), 55 patients (68.8 %) developed a recur-
rence. Overall, 49 patients (61.3 %) died as a result of the
recurrent disease and 6 patients with recurrence were still
alive at the end of the study. The median SUVmean (used
for further analysis) was 6.49 (IQR 4.5–10.9) and the median
log(SUVmean) was 1.86.
The 5-year DFS in patients with a low SUVmean was
40.9 % (95% CI 25.5–55.7 %) and 24.2 % (95%CI 12.4–
38.0 %) in patients with a high SUVmean (p00.02), as
shown in Fig. 2. Webtable 1 shows the univariate and
multivariable analysis of DFS, and Table 2 shows the
analysis of DFS in relation to SUV. SUVmean was
associated with DFS with a hazard ratio (HR) of 1.7
(95% CI 1.0–3.0; p00.048). Other variables associated
with DFS in the multivariable analysis were the number
of positive nodes (HR 1.1, 95% CI 1.0–1.2; p00.02)
and the presence of extranodal growth (HR 3.4, 95% CI
1.4–4.2; p00.003).
The 5-year DSS was 47.5 % (95% CI 30.9–62.3) in
patients with a low SUVmean and 30.3 % (95% CI 16.7–
45.0) for patients with a high SUVmean (p00.02, Fig. 2).
Webtable 2 shows the univariate and multivariable analysis
of DSS, and Table 2 shows the analysis of DSS in relation to
SUV. SUVmean was not associated with DSS in the multi-
variable analysis (HR 1.6, 95% CI 0.9–2.9; p00.1). Female
gender was associated with a better DSS in the multivariable
analysis (HR 0.5, 95% CI 0.3–0.8; p00.009).
Table 1 Patient and tumour characteristics of the 80 patients with palpa-
ble, histology- or cytology-proven lymph node metastases of melanoma
Characteristic Value
Gender, n (%) Men 39 (48.8)
Women 41 (51.2)




Location, n (%) Upper extremities 9 (11.2)
Lower extremities 34 (42.5)
Trunk 29 (36.3)
Head and neck 6 (7.5)
Unknown primary 2 (2.5)
Breslow thickness (mm), n (%) ≤1.0 10 (12.5)
1.0–2.0 27 (33.8)
≥2.0 41 (51.2)
Unknown primary 2 (2.5)
Ulceration, n (%) No 63 (78.8)
Yes 15 (18.7)
Unknown primary 2 (2.5)
Lymph node metastases
Location, n (%) Cervical region 10 (12.5)
Axilla 26 (32.5)
Groin 44 (55.0)
Removed nodes, median (range) 16 (7–48)
Positive nodes, median (range) 2 (1–19)
Tumour size, median (range) 3.1 (0.5–7.0)
Extranodal growth, n (%) No 55 (68.8)
Yes 25 (31.2)
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Discussion
The present prospective study endorses the prognostic value
of SUV in terms of DFS in patients with stage IIIB melano-
ma who have been optimally staged with FDG PET and CT.
The use of SUV as a quantitative parameter of FDG uptake
has a long tradition in nuclear medicine [14]. Although its
value for predicting tumour response to therapy has become
generally accepted, the clinical usefulness and applicability
of SUV for prognostic purposes is still under discussion.
As far as the authors are aware there are two other studies
(from our group) that addressed the value of SUV in mela-
noma patients [13, 22]. The first study was a small retro-
spective study that showed no significant association
between SUVmean and survival (p00.11); however, DFS
was significantly decreased in patients with a high SUVmean
(p00.03) [13]. The study by Kruijff et al. showed no association
between SUVand survival [22]. There are, however, significant
differences between the patients in the two databases, especially
in location, number of positive nodes (more in the present study)
and percentage of patients with extranodal growth (lower per-
centage in the present study). Furthermore, the cut-off values in
both studies were data-driven and differ. In the present prospec-
tive study we confirmed the association found in the retrospec-
tive study [13]. There was a significantly decreased DFS in
patients with a high SUVmean in the lymph node metastasis
(p00.048). An association between SUVmean and survival was
not found. DSS was, however, associated with gender, as
reported previously by De Vries et al. [23]. Among 10,538
melanoma patients, women had a superior survival than men
even after adjustment for multiple confounding variables [23].
Probably factors other than stage at diagnosis and location
reduces mortality risk in female melanoma patients. The asso-





























Fig. 1 Distributions of the
SUVmean and SUVmax values
in comparison with the normal
(gaussian) distributions
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have been reported before: extranodal growth showed a stronger
association with DFS than SUVmean [24].
Some of the primary melanoma characteristics such as
Breslow thickness and ulceration were not associated with
survival in these patients with macrometastatic disease. In-
terestingly, a recent study by Balch et al. showed similar
results: in patients with nodal micrometastases, multiple
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Fig. 2 Kaplan Meier curves for
DFS and DSS in patients with a
high and low SUV
Table 2 Multivariable analyses of DFS and DSS for the patients with Stage III melanoma
Variable DFSa DSSb
Hazard ratio p value Hazard ratio p value
SUVc Low 1 (reference) 0.048 1 (reference) 0.1
High 1.74 (1.00–3.00) 1.57 (0.86–2.87)
a Adjusted for positive nodes and extranodal growth (see Webtable).
b Adjusted for sex, positive nodes and extranodal growth (see Webtable).
c Divided by the median of log(SUVmean)01.86.
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several primary melanoma features (thickness, mitotic
rate, ulceration, and anatomic site of the primary tu-
mour) [25]. In contrast, in patients with nodal macro-
metastases, primary melanoma characteristics did not
predict survival. Remarkably, there was no clear signif-
icant association between tumour size and survival in
the present study. A longer follow-up of the patients
might have altered these outcomes. Categorization of
tumour size into <3 cm or ≥3 cm did not lead to different
results (DFS HR 1.7, 95% CI 1.0–3.0), p00.1; DSS HR 1.7,
95% CI 1.0–3.2, p00.1). Unfortunately, we were not able to
stratify according to tumour size. Further, larger studies
should possibly involve stratification according to smaller
and larger tumour in the lymph nodes.
We present a single-centre study with standardized
PET procedures to obtain homogeneity at that level.
Since the measured SUV is a function of many techni-
cal and biological factors, the absolute values are only
generalizable if these are taken into account. A recent
study by Westerterp et al. showed differences in SUV
quantification between institutes with different PET
scanners [26]. Consequently, standardization of acquisi-
tion, reconstruction and data analysis is needed for
multicentre trials. When the present study was initiated,
there were no guidelines on how to harmonize the
results of multicentre studies using different scanners,
acquisition and reconstruction protocols. However, pro-
vided that the 2010 PET guidelines for trials and clin-
ical practice are followed [27], this is no longer an
obstacle, and hopefully the evidence for the potential
of quantitative PET in oncology will mature rapidly. In
the present study we used the median value of the log-
transformed SUVmean for risk stratification. However,
there is always change for bias if data-driven cut-off
values are used. To be a practical prognostic factor in
routine practice, standardization of protocols and cut-off
values for SUV should be agreed upon or the method-
ology to determine the optimal threshold for each centre
should be established [17].
As a FDG PET scan as a staging procedure prior to
treatment of metastatic melanoma in regional lymph nodes
is now performed, determination of SUV values would
provide additional information at very little extra cost. In
conclusion, in patients with clinical stage III melanoma, a
high SUVmean was associated with decreased DFS. If con-
firmed in larger studies, SUVmean could potentially be
used, in addition to the number of positive nodes, tumour
size and extranodal growth, as a factor in deciding on
adjuvant systemic treatment.
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